New drug combo aims to prevent myeloma relapse after stem cell transplant
NCT ID NCT02420860
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 27 times
Summary
This study tests whether adding elotuzumab to standard lenalidomide maintenance therapy can help keep multiple myeloma from returning after a stem cell transplant. About 113 people who recently had a transplant using their own stem cells will receive the drug combination. The goal is to see if the combo improves how long the cancer stays away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.